A. Inoue

T. Nukiwa, S. Sugawara, A. Inoue, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Inhibition of proteasome activity is involved in cobalt-induced apoptosis of human alveolar macrophages.

Masashi Kobayashi, J. Araya, A. Inoue, 2002, American journal of physiology. Lung cellular and molecular physiology.

Prospective analysis of the epidermal growth factor receptor gene mutations in non-small cell lung cancer in Japan.

S. Suzuki, T. Nukiwa, T. Kondo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies

A. Gemma, Kunihiko Kobayashi, S. Oizumi, 2015, Expert opinion on pharmacotherapy.

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.

M. Maemondo, T. Nukiwa, Takuji Suzuki, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of biweekly nab‐paclitaxel in patients with platinum‐pretreated non‐small cell lung cancer: NJLCG1402

T. Harada, T. Nakagawa, A. Inoue, 2021, Thoracic cancer.

Effects of molecular targeting agents and immune-checkpoint inhibitors in patients with advanced cancer who are near the end of life

T. Hori, A. Inoue, A. Yoshioka, 2021, Palliative and Supportive Care.

Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer

T. Hori, K. Nagashima, A. Inoue, 2018, International Journal of Clinical Oncology.

Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study.

K. Kiura, H. Ueoka, M. Tanimoto, 2005, Lung cancer.

Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.

M. Ando, Y. Hasegawa, S. Yano, 2017, The journal of medical investigation : JMI.

METex14 Skipping Testing Guidance for Lung Cancer Patients: The Guidance from the Biomarker Committee, the Japan Lung Cancer Society

S. Toyooka, S. Ikeda, Y. Yatabe, 2021, Haigan.

VII. Developments of Chemotherapy and Improvements of Prognosis in Lung Cancer

A. Inoue, 2016 .

Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts.

K. Sugamura, M. Maemondo, T. Nukiwa, 2004, Cancer research.

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

Kenji Eguchi, Masahiro Tsuboi, Masahiro Fukuoka, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non–Small Cell Lung Cancer

A. Gemma, M. Soda, Y. Yamashita, 2012, Clinical Cancer Research.

Sensitive and Specific New Enzyme-Linked Immunosorbent Assay for N-ERC/Mesothelin Increases its Potential as a Useful Serum Tumor Marker for Mesothelioma

Kazuhisa Takahashi, M. Maeda, O. Hino, 2008, Clinical Cancer Research.

Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first‐line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)

T. Harada, M. Maemondo, A. Inoue, 2019, Thoracic cancer.

Patient perceptions of curability and physician-reported disclosures of incurability in Japanese patients with unresectable/recurrent cancer: a cross-sectional survey

C. Ishioka, H. Shimodaira, Kazuki Sato, 2018, Japanese journal of clinical oncology.

[A case of Goodpasture's syndrome with myeloperoxidase specific anti-neutrophil cytoplasmic autoantibody (MPO-ANCA) during chronic interstitial pneumonia].

Y. Ono, A. Inoue, T. Suzuki, 1997, Nihon Kyobu Shikkan Gakkai zasshi.

The Role of "Early Palliative Care" in Treatments of Advanced Lung Cancer

A. Inoue, 2020, Haigan.

- 1-Comparisons and combinations of the five tumor markers for mesothelioma : NERC / mesothelin , osteopontin , hyaluronic acid , CA 125 , and CYFRA 21-1

Kenji Suzuki, Kazuhisa Takahashi, M. Maeda, 2011 .

Sensitive and Specific New Enzyme-Linked Immunosorbent Assay for NERC / Mesothelin Increases its Potential as a Useful Serum TumorMarker for Mesothelioma

Kazuhisa Takahashi, O. Hino, Y. Sakao, 2008 .

[Chronic eosinophilic pneumonia associated with high concentrations of interleukin-5, -6, and granulocyte colony stimulating factor in serum and in pleural fluid].

A. Inoue, T. Suzuki, Y. Shindoh, 1997, Nihon Kyobu Shikkan Gakkai zasshi.

Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas

T. Okazaki, R. Saito, M. Ichinose, 2019, Molecular Cancer.

Phase II study of S-1 and irinotecan combination therapy in EGFR-mutated non-small cell lung cancer resistant to epidermal growth factor receptor tyrosine kinase inhibitor: North Japan Lung Cancer Study Group Trial 0804 (NJLCG0804)

T. Harada, S. Sugawara, A. Inoue, 2022, Medical Oncology.

P1.01-33 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR study)

T. Yamanaka, M. Satouchi, K. Yoh, 2018, Journal of Thoracic Oncology.

A Phase I Study of Amrubicin Combined with Carboplatin for Elderly Patients with Small-Cell Lung Cancer

M. Nishimura, K. Yamazaki, M. Maemondo, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan Lung Cancer Group 1101 (NJLCG1101)

T. Harada, S. Sugawara, A. Inoue, 2021 .

Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry.

E. Miyaoka, K. Kiura, I. Yoshino, 2020, Lung cancer.

Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.

S. Oizumi, M. Maemondo, T. Nukiwa, 2015, Lung cancer.

A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer.

N. Saijo, N. Yamamoto, T. Tamura, 2001, Japanese journal of clinical oncology.

Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).

A. Gemma, Y. Hosomi, S. Morita, 2018 .

Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803

Kunihiko Kobayashi, M. Maemondo, T. Nukiwa, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001

N. Yoshimura, M. Maemondo, T. Nakagawa, 2019, Translational lung cancer research.

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.

A. Gemma, Y. Hosomi, S. Morita, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated Data of a Phase 1/2 Study (AF-001JP) of Alectinib, a CNS-Penetrant, Highly Selective ALK Inhibitor in ALK-rearranged Advanced NSCLC

Y. Ohe, K. Kikuchi, M. Maemondo, 2014 .

A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK+ NSCLC) patients (pts): Updates on progression free survival (PFS) and safety results from AF-001JP.

Y. Ohe, K. Kiura, M. Maemondo, 2015 .

A Phase I/II Study of Alk Inhibitor CH5424802 in Patients With Alk-Positive Nsclc; Safety and Efficacy Interim Results of the Phase II Portion

K. Kiura, M. Maemondo, M. Nishio, 2012 .

Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?

Akira Inoue, N. Reinmuth, W. Dempke, 2015, Anticancer research.

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR

Y. Hosomi, M. Seike, S. Morita, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Immune Checkpoint Therapy for Non-Small-Cell Lung Cancer].

A. Inoue, E. Miyauchi, 2016, Gan to kagaku ryoho. Cancer & chemotherapy.

Successful crizotinib retreatment after crizotinib-induced interstitial lung disease.

M. Ichinose, A. Koarai, A. Inoue, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Loss of ARID1A Promotes Epithelial–Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress

Justin K. Huang, A. Maitra, G. Genovese, 2020, Cancer Research.

First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non–Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study

S. Kudoh, Tomoaki Tanaka, Kunihiko Kobayashi, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations

Koichi Yamazaki, Satoshi Morita, Masahiro Fukuoka, 2009, Clinical Cancer Research.

Frequency of and variables associated with the EGFR mutation and its subtypes

A. Gemma, K. Uematsu, Tomoaki Tanaka, 2010, International journal of cancer.

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

V. Gebski, N. Pavlakis, T. Mitsudomi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Severe acute interstitial pneumonia and gefitinib

M. Ebina, M. Maemondo, T. Nukiwa, 2003, The Lancet.

Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research

S. Kopetz, T. Heffernan, G. Draetta, 2019, Cancers.

Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure

Jesse R. Dixon, R. Verhaak, P. Futreal, 2020, Nature genetics.

Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

N. Socci, A. Viale, M. Ladanyi, 2011, Science Translational Medicine.

A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients

E. Miyaoka, K. Kiura, H. Dosaka-akita, 2020, Cancer science.

Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations

Keunchil Park, M. Fukuoka, K. Kiura, 2018, Cancer science.

ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer

M. Fukuoka, K. Kiura, M. Satouchi, 2018, Cancer science.

Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203.

T. Harada, M. Ichinose, T. Nakagawa, 2019, Lung Cancer.

Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q

Koichi Hagiwara, Yuji Minegishi, Akira Inoue, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.

Y. Ichinose, K. Kiura, K. Goto, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of amrubicin (AMR) and carboplatin (CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC): NJLCG0803.

Kunihiko Kobayashi, M. Maemondo, T. Nukiwa, 2013 .

Randomized Phase II Study of Two Schedules of Carboplatin and Gemcitabine for Stage IIIB and IV Advanced Non-Small Cell Lung Cancer (JACCRO LC-01 Study)

M. Tsuboi, N. Ikeda, J. Uchida, 2011, Chemotherapy.

Juliann Chmielecki with Evolutionary Cancer Modeling Small Cell Lung Cancer − Optimization of Dosing for EGFR-Mutant Non

N. Socci, A. Viale, M. Ladanyi, 2011 .

Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib

M. Nishimura, H. Dosaka-akita, S. Oizumi, 2011, Oncology.

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients

M. Fukuoka, S. Morita, I. Okamoto, 2016, Japanese journal of clinical oncology.

Anterior Gradient 2 is Correlated with EGFR Mutation in Lung Adenocarcinoma Tissues

Takashi Suzuki, H. Sasano, Y. Miki, 2015, The International journal of biological markers.

A prospective PCR – based screening for the EML 4-ALK oncogene in non-small cell lung cancer Running title : PCR – based screening for EML 4-ALK

A. Gemma, M. Soda, Y. Yamashita, 2012 .

Imaging , Diagnosis , Prognosis A Prospective PCR-Based Screening for the EML 4-ALK Oncogene in Non – Small Cell Lung Cancer

A. Gemma, M. Soda, Y. Yamashita, 2012 .

Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer.

H. Sasano, T. Nukiwa, M. Ichinose, 2014, Respiratory investigation.

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

Y. Ohe, K. Kiura, M. Maemondo, 2013, The Lancet. Oncology.

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

V. Gebski, S. Thongprasert, D. Chu, 2013, Journal of the National Cancer Institute.

Retrospective Analysis of Acquired Resistance During the Treatment with Gefitinib in Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutations

M. Ebina, T. Nukiwa, A. Inoue, 2009 .

Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.

T. Harada, M. Maemondo, T. Nukiwa, 2017, Lung cancer.

Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.

A. Gemma, M. Seike, H. Saka, 2021, The Lancet. Healthy longevity.

Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302

T. Harada, T. Nakagawa, S. Sugawara, 2020, International Journal of Clinical Oncology.

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

V. Gebski, I. Marschner, T. Mitsudomi, 2017, Journal of the National Cancer Institute.

Randomized phase II study of concurrent versus sequential alternating ge fi tinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations : NEJ 005 / TCOG 0902

A. Gemma, S. Morita, M. Kurihara, 2015 .

Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment.

T. Nukiwa, A. Inoue, N. Nishimura, 2012, Respiratory investigation.

Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).

A. Gemma, Kunihiko Kobayashi, S. Oizumi, 2015, Japanese journal of clinical oncology.

Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer

A. Inoue, 2020, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database.

E. Miyaoka, K. Kiura, I. Yoshino, 2020, Lung cancer.

Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression

Young Hak Kim, Y. Hosomi, Y. Tomizawa, 2018, Expert opinion on pharmacotherapy.

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.

Y. Ohe, M. Fukuoka, S. Morita, 2018, Lung cancer.

Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations

A. Gemma, S. Morita, Kunihiko Kobayashi, 2018, ESMO Open.

Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study

Young Hak Kim, Y. Hosomi, Y. Tomizawa, 2017, ESMO Open.

Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.

A. Gemma, S. Morita, Kunihiko Kobayashi, 2015, Lung cancer.

A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial

A. Gemma, S. Kudoh, H. Ohmatsu, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.

A. Gemma, S. Morita, M. Kurihara, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Low-Dose Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations

A. Gemma, Kunihiko Kobayashi, S. Oizumi, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Sequential administration of XPO1 and ATR inhibitors enhances therapeutic response in TP53-mutated colorectal cancer.

G. Genovese, C. Bristow, S. Seth, 2021, Gastroenterology.

Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene.

T. Nukiwa, S. Sugawara, A. Inoue, 2000, Cancer letters.

A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405.

S. Ogura, T. Harada, S. Oizumi, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer.

N. Saijo, Y. Ohe, Hirokazu Watanabe, 2003, Japanese journal of clinical oncology.

Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer.

K. Mori, N. Saijo, M. Fukuoka, 2002, Lung cancer.

A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016)

A. Gemma, Kunihiko Kobayashi, T. Harada, 2017, Investigational New Drugs.

Inhibition of Experimental Metastasis of Human Fibrosarcoma Cells by Anti‐recombinant 37‐kDa Laminin Binding Protein Antibody

T. Abe, T. Nukiwa, M. Isemura, 1999, Japanese journal of cancer research : Gann.

Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer

P. A. Futreal, Jing Wang, I. Wistuba, 2018, Nature Medicine.

Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)

Y. Ohe, K. Kiura, M. Maemondo, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

An analysis of the relationship between metastases and cachexia in lung cancer patients

A. Borczuk, Swarnali Acharyya, Ying Wei, 2016, Cancer medicine.

A Randomized Phase III Study Comparing Carboplatin With Nab‐Paclitaxel Versus Docetaxel for Elderly Patients With Squamous‐Cell Lung Cancer: Study Protocol

A. Gemma, T. Yamanaka, Y. Ichinose, 2018, Clinical lung cancer.

Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301

T. Harada, M. Maemondo, Toshiro Suzuki, 2017, The oncologist.

Association between mycobacterial genotypes and disease progression in Mycobacterium avium pulmonary infection

M. Ebina, M. Kaku, T. Nukiwa, 2009, Thorax.

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC

A. Gemma, Y. Ichinose, Y. Ohe, 2019, International Journal of Clinical Oncology.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease.

M. Ichinose, A. Inoue, E. Miyauchi, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.

A. Gemma, Kunihiko Kobayashi, S. Oizumi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G).

Y. Ichinose, H. Saka, K. Kiura, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: Updated safety and efficacy results from AF-001JP.

Y. Ohe, K. Kiura, M. Maemondo, 2013 .

A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901.

M. Nishimura, H. Dosaka-akita, F. Hommura, 2013, The oncologist.

Randomized phase III trial of S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer (TCOG0701).

A. Gemma, S. Kudoh, H. Ohmatsu, 2012 .

Randomized Phase III Trial of S-1 plus Cisplatin versus Docetaxel plus Cisplatin for Advanced Non-Small-Cell Lung Cancer TCOG 0701 CATS (Cisplatin And TS-1) Trial 1234

A. Gemma, S. Kudoh, M. Takeuchi, 2012 .

Randomized phase II trial of uracil/tegafur and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small-cell lung cancer: NJLCG 0601.

M. Maemondo, T. Nukiwa, T. Ishida, 2013, Lung cancer.

Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas

T. Okazaki, R. Saito, M. Ichinose, 2019, Molecular Cancer.

Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma

H. Sasano, Y. Miki, H. Kumamoto, 2012, British Journal of Cancer.

Benefits of a Nationwide Palliative Care Education Program on Lung Cancer Physicians

Takuhiro Yamaguchi, N. Seki, A. Inoue, 2019, Internal medicine.

Gefitinib combined survival analysis of the mutation positives from the prospective phase II trials (I-CAMP)

T. Mitsudomi, N. Sunaga, K. Sugio, 2008 .

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP

Y. Ohe, K. Kiura, M. Maemondo, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Case of Small-cell Lung Carcinoma with EGFR Gene Mutation

T. Nukiwa, A. Inoue, T. Sakakibara, 2011 .

Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting.

Y. Hosomi, K. Mori, Y. Tomizawa, 2017, Anticancer research.

Establishment of a research policy for supportive and palliative care in Japan

T. Morita, Takuhiro Yamaguchi, Y. Uchitomi, 2021, Japanese journal of clinical oncology.

siRNA Targeting against EGFR, a Promising Candidate for a Novel Therapeutic Application to Lung Adenocarcinoma

A. Sakurada, K. Inomata, A. Horii, 2008, Pathobiology.

Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study

A. Gemma, H. Saka, Y. Kogure, 2023, JTO Clinical and Research Reports.

The "value" of immune-checkpoint inhibitors for advanced lung cancer.

A. Inoue, 2017, Respiratory investigation.

OA 05.08 Final Result of Phase I/II Study (AF-001JP) of Alectinib, a Selective CNS-Active ALK Inhibitor, in ALK+ NSCLC Patients (Pts)

Y. Ohe, K. Kiura, M. Maemondo, 2017 .

Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.

S. Oizumi, M. Maemondo, T. Nukiwa, 2014, Respiratory investigation.

Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.

M. Maemondo, T. Nukiwa, S. Sugawara, 2015, Respiratory Investigation.

First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study.

A. Inoue, Y. Tsukita, 2022, Japanese journal of clinical oncology.

Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion.

Kunihiko Kobayashi, T. Nukiwa, Satoshi Watanabe, 2015, Anticancer research.

S-1 Combined with Bi-Weekly Docetaxel for Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy: A Phase II Study of North Japan Lung Cancer Group (NJLCG0701)

M. Maemondo, T. Nukiwa, Toshiro Suzuki, 2012 .

A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer.

T. Nukiwa, Masashi Tanaka, A. Inoue, 2006, Lung cancer.

Two cases of pseudo-achalasia with lung cancer: Case report and short literature review.

M. Ichinose, T. Kikuchi, S. Chiba, 2016, Respiratory investigation.

Phase I/II study of alectinib (CH5424802/RO5424802) in patients with alk-rearranged non-small cell lung cancer (NSCLC): Updated results from the AF-001JP trial

K. Kiura, M. Maemondo, M. Nishio, 2014 .

Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis.

N. Saijo, H. Kunitoh, A. Inoue, 2001, International journal of radiation oncology, biology, physics.

An analysis of the relationship between metastases and cachexia in lung cancer patients

A. Borczuk, Swarnali Acharyya, Ying Wei, 2016, Cancer medicine.

9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study

S. Morita, S. Oizumi, M. Maemondo, 2009 .

1471PFINAL RESULT OF RANDOMIZED PHASE 2 TRIAL COMPARING AMRUBICIN (A) WITH RE-CHALLENGE OF PLATINUM DOUBLET (P) IN PATIENTS (PTS) WITH SENSITIVE-RELAPSED SMALL-CELL LUNG CANCER (SCLC): NJLCG0702.

S. Oizumi, M. Maemondo, T. Nukiwa, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Concurrent cisplatin/etoposide (PE) and twice-daily thoracic radiotherapy (BID TRT) followed by weekly dose intensive regimen (CODE) with human granulocyte-colony stimulating factor (G-CSF) for limited stage (LS) small cell lung cancer (SCLC)

N. Saijo, Y. Nishiwaki, Y. Ohe, 2000 .

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

V. Gebski, S. Thongprasert, D. Chu, 2013, Journal of the National Cancer Institute.

LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.

Y. Ichinose, K. Kiura, K. Goto, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of weekly paclitaxel and carboplatin for elderly patients with advanced non-small cell lung cancer (NSCLC)

T. Nukiwa, Masashi Tanaka, A. Inoue, 2005 .

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.

A. Gemma, T. Harada, S. Oizumi, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line gefitinib for elderly patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: A combined analysis of NEJ studies.

A. Gemma, T. Harada, M. Maemondo, 2012 .

NEJ009 trial: A randomized phase III study of gefitinib (G) in combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation.

A. Gemma, Y. Hosomi, S. Morita, 2014 .

Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer

P. A. Futreal, Jing Wang, I. Wistuba, 2018, Nature Medicine.

A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial

A. Gemma, H. Ohmatsu, S. Sugawara, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

P1.01-08 Randomized Phase II Trial of CBDCA+nab-PTX vs CDDP+GEM in Patients with Chemo-Naïve Squamous Cell Lung Cancer: NJLCG1302

T. Harada, T. Nakagawa, S. Sugawara, 2019, Journal of Thoracic Oncology.

Randomized phase II trial comparing carboplatin plus weekly paclitaxel and docetaxel alone in elderly patients with advanced non-small cell lung cancer: north japan lung cancer group trial 0801.

A. Gemma, T. Harada, M. Maemondo, 2014, The oncologist.

Phase II trial of daily S‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101

T. Harada, S. Sugawara, A. Inoue, 2023, Thoracic cancer.